May, 2024
May 2024
Emre Yekedüz: A retrospective study from Gustave Roussy
Apr 16, 2024, 12:58

Emre Yekedüz: A retrospective study from Gustave Roussy

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at , made the following post on X:

“How is it safe to use steroids and immune-suppressive (IS) agents in cancer patients treated with immune checkpoint inhibitors and who experienced grade 2 or higher immune-related adverse events?
A retrospective study from Gustave Roussy:

  • 184 patients treated with ICB, all experienced at least one grade ≥2 irAE.
  • 107 patients were treated with steroids alone, 20 patients received steroids plus IS, 57 patients did not receive steroids or IS.
  • Patients treated with only steroids had the shortest OS and PFS.
  • The data suggests that the use of steroids alone may be associated with shorter survival outcomes in ICB-treated patients.

Early use of IS agents rather than high-dose steroids alone might serve better survival outcomes!!!”

Source: Emre Yekedüz/X

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”